Amgen stock trades at EUR 362.13, market cap USD 218.8 billion

Published on 10/08/2026 at 20:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock costs EUR 362.13 on October 8, 2026 after EUR 368.60. Nasdaq price was USD 405.43 on October 8, 2026.

Key points in brief

Amgen stock was EUR 362.13 at Lang & Schwarz on October 8, 2026, down 1.76 percent from EUR 368.60.
The Nasdaq quote was USD 405.43 at 2:40 p.m. ET, while the 52-week range was USD 288.00 to USD 447.03.
Amgen's market capitalization was USD 218.8 billion and its P/E ratio was 25.21.
Amgen's investor calendar lists the Wells Fargo 21st Annual Healthcare Conference for October 9, 2026.

Editorial-Aufnahme eines Nasdaq-Handelssaals mit großen Bildschirmen und steigenden Biotech-Sektor-Kurscharts — Amgen Inc. (ISIN US0311621009) thematisiert dieses Börsen-Editorial mit Nasdaq-Handelssaal und ansteigenden Biotech-Sektor-Kurscharts auf großen Bildschirmen, Illustration mit AI erstellt.

Amgen stock (ISIN US0311621009) was at EUR 362.13 at Lang & Schwarz on October 8, 2026 at 8:36 p.m. CEST, while its market capitalization was USD 218.8 billion. The euro quote was down 1.76 percent from the Lang & Schwarz prior close of EUR 368.60 on October 7, 2026.

Nasdaq quote and yearly range

On the Nasdaq, Amgen was last at USD 405.43 on October 8, 2026 at 2:40 p.m. ET. The primary-market quote was intraday, so it is separate from the after-hours euro price at Lang & Schwarz.

Amgen's 52-week range was USD 288.00 to USD 447.03 as of October 8, 2026. The latest Nasdaq price therefore stood USD 41.60 below the 52-week high, while the Lang & Schwarz quote used for German investors was stated in euros.

Valuation carries the market view

Amgen's P/E ratio was 25.21 on October 8, 2026, alongside a market capitalization of USD 218.8 billion. The combination gives the stock report a valuation angle without mixing the Nasdaq dollar quote with the Lang & Schwarz euro quotation.

The most recent quarterly figures cover the second quarter of 2026, which ended June 30, 2026. Revenue reached USD 10.05 billion and consolidated net income was USD 2.38 billion for that period, while diluted earnings per share were USD 4.37.

Comparison with peers

Amgen: minus 1.76 percent, P/E 25.21, market capitalization USD 218.8 billion

Gilead Sciences (NASDAQ, USD): minus 0.11 percent, P/E minus 54.95, market capitalization USD 181.9 billion

Regeneron Pharmaceuticals (NASDAQ, USD): minus 0.80 percent, P/E 18.19, market capitalization USD 75.8 billion

Next scheduled investor event

Amgen lists the Wells Fargo 21st Annual Healthcare Conference for October 9, 2026. The event date is the next item shown in the company's investor calendar, while the next quarterly reporting date remains outside the calendar entry used here.

After-hours quote and prior close

At Lang & Schwarz, Amgen stood at EUR 362.13 after-hours on October 8, 2026 at 8:36 p.m. CEST, compared with EUR 368.60 for the prior close on October 7, 2026. The euro move was minus 1.76 percent.

The further course of trading is shown by the continuously updated real-time quote of Amgen stock.